<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Heart transplantation in adults: Graft dysfunction</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Heart transplantation in adults: Graft dysfunction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Heart transplantation in adults: Graft dysfunction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael X Pham, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sharon A Hunt, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The development of ventricular dysfunction after cardiac transplantation, which can be systolic, diastolic, or mixed, should be of major concern. The causes of graft dysfunction in the transplanted heart can be different, more ominous, and in some cases more responsive to treatment than those seen in the native heart. As a result, familiarity with the potential etiologies, coupled with an aggressive and systematic approach, is essential to identify the etiology and begin prompt treatment.</p><p>Graft dysfunction can occur as early as the intraoperative period or can develop many years after transplantation. The timing of graft dysfunction (days, weeks to months, or years post-transplantation) is one of the most important clues to establish a diagnosis. Graft dysfunction may present as either heart failure with preserved or reduced ejection fraction, asymptomatic ventricular dysfunction, or by elevated intracardiac filling pressures or depressed cardiac output on right heart catheterization. It can affect the right, left, or both ventricles.</p><p>The most common causes of graft dysfunction after transplantation include primary graft dysfunction, which manifests within 24 hours after surgery; cardiac allograft rejection, which is more common during the first 6 to 12 months post-transplantation; and cardiac allograft vasculopathy, which can occur at any time. Diagnostic procedures such as endomyocardial biopsy, echocardiography, and coronary angiography are important tools in elucidating the etiology, but all these studies have their limitations. (See  <a class="medical medical_review" href="/d/html/3519.html" rel="external">"Heart transplantation in adults: Diagnosis of allograft rejection"</a> and  <a class="medical medical_review" href="/d/html/4923.html" rel="external">"Endomyocardial biopsy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EARLY GRAFT DYSFUNCTION</span><span class="headingEndMark"> — </span>Early allograft dysfunction can be apparent in the intraoperative period or can develop within the hours to days after transplant surgery. It can manifest as left ventricular (LV) dysfunction, isolated right ventricular (RV) dysfunction, or biventricular dysfunction, and it is associated with significantly increased 30-day and one-year mortality. Early graft dysfunction is classified as primary or secondary graft dysfunction according to the suspected etiology.</p><p class="headingAnchor" id="H20689079"><span class="h2">Primary graft dysfunction</span><span class="headingEndMark"> — </span>Primary graft dysfunction (PGD) is currently defined as LV, RV, or biventricular dysfunction that occurs within 24 hours after surgery and is not associated with a discernible cause such as hyperacute rejection, pulmonary hypertension, massive blood product transfusion during surgery, or prolonged graft ischemic time. PGD can affect the LV, RV, or both ventricles.</p><p>A classification system has been proposed by the International Society of Heart and Lung Transplantation based upon the ventricle affected and the degree of hemodynamic compromise [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PGD of the LV (PGD-LV):</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>LV ejection fraction (LVEF) ≤40 percent by echocardiography, or hemodynamics with right atrial pressure (RAP) &gt;15 mmHg, pulmonary capillary wedge pressure (PCWP) &gt;20 mmHg, and cardiac index (CI) &lt;2.0 L/min/m<sup>2</sup> (lasting more than one hour) requiring low-dose inotropes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>LVEF ≤40 percent, or<em> </em>hemodynamic compromise with RAP &gt;15 mmHg, PCWP &gt;20 mmHg, CI &lt;2.0 L/min/m<sup>2</sup>, and hypotension with mean arterial pressure &lt;70 mmHg (lasting more than 1 hour).</p><p></p><p class="bulletIndent3"><strong>and</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Requirement for high-dose inotropes or newly placed intraaortic balloon pump.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Requirement for left or biventricular mechanical support such as extracorporeal membrane oxygenation, left ventricular assist device (LVAD), biventricular assist device, or percutaneous LVAD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PGD of the RV (PGD-RV):</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamics with RAP &gt;15 mmHg, PCWP &lt;15 mmHg, CI &lt;2.0 L/min/m<sup>2</sup></p><p></p><p class="bulletIndent2"><strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transpulmonary gradient &lt;15 mmHg and/or pulmonary artery systolic pressure &lt;50 mmHg</p><p></p><p class="bulletIndent2"><strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Need for right ventricular assist device</p><p></p><p>In practice, we also observe biventricular dysfunction, and these cases are classified under PGD-LV. Based on aggregate data from multiple centers, the incidence of mild LV, moderate LV, severe LV, and isolated RV PGD was 3.5, 6.6, 7.7, and 1.6 percent, and the one-year mortality rates were 15, 21, 41, and 35 percent. Risk factors for PGD included donor characteristics (female sex and undersized heart), recipient factors (serum creatinine, pretransplant use of <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> and temporary mechanical circulatory support), and prolonged graft ischemic time [<a href="#rid2">2</a>].</p><p>Although the etiology of PGD is poorly understood, it is felt that preexisting donor and recipient risk factors; injury to the donor heart during brain death; ischemia during the process of organ recovery, preservation, and re-implantation; and reperfusion injury immediately after reimplantation of the allograft and release of the aortic cross-clamp may contribute to the development of PGD.</p><p class="headingAnchor" id="H4"><span class="h3">Ischemic and reperfusion injury during surgery</span><span class="headingEndMark"> — </span>Allograft injury can result from prolonged allograft ischemic time as well as from reperfusion injury immediately following reperfusion of the allograft with the recipient’s circulation. Ischemic time refers to the time from cross clamping the donor, with subsequent excision and immersion of the heart in iced <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, to removal of the cross clamp after implantation in the recipient. When using traditional static cold storage, whereby the heart is arrested (ie, placed in a crystalloid preservation solution, and stored on ice until the time of implantation), total ischemic time greater than four hours has been associated with an increased risk of PGD [<a href="#rid3">3</a>], and hearts from older donors are more susceptible to ischemic injury [<a href="#rid4">4</a>]. The injury to the allograft may be transient (myocardial stunning), lasting for 12 to 24 hours after transplantation in some cases [<a href="#rid5">5</a>], but contraction band necrosis and other evidence of ischemic injury can be seen in biopsy specimens from persistently dysfunctional hearts as well as those with functional recovery [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Suboptimal donor heart</span><span class="headingEndMark"> — </span>Although the pool of potential heart recipients has increased, the donor pool has remained relatively stable [<a href="#rid7">7</a>]. As a result, some transplant programs have begun to consider and accept hearts from "suboptimal" donors (eg, patients over age 55 and those with mild LV hypertrophy or non-obstructive coronary artery disease) [<a href="#rid8">8-10</a>]. Additionally, some donor hearts have been subjected to higher doses of intravenous inotropes or pressor amines or have evidence of LV dysfunction attributed to the effects of brain death. Hearts from patients with significant LV hypertrophy, valvular heart disease, or obstructive coronary artery disease are still usually avoided, as are hearts damaged from trauma.</p><p class="headingAnchor" id="H355015131"><span class="h3">Prevention</span><span class="headingEndMark"> — </span>Although PGD cannot always be prevented, the combination of using a suboptimal donor heart with prolonged static cold storage should be avoided whenever possible. Other factors that may ameliorate the effects of prolonged ischemic time include temperature-controlled cold preservation [<a href="#rid11">11</a>] and normothermic ex vivo organ perfusion, which allows preservation of the heart in a beating state by perfusing it with a warmed, donor-blood-based solution that is supplemented with nutrients and oxygen [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/d/html/1511.html" rel="external">"Reperfusion injury of the heart"</a>.)</p><p class="headingAnchor" id="H100130288"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Treatment options for PGD include the use of high-dose inotropic agents to support LV and RV function and the use of <a class="drug drug_general" data-topicid="9447" href="/d/drug information/9447.html" rel="external">inhaled nitric oxide</a> for RV dysfunction. If medical management does not improve the patient’s hemodynamics, then early initiation of mechanical circulatory support with an intraaortic balloon pump, extracorporeal membrane oxygenator, or temporary ventricular assist device is recommended before the development of severe end-organ dysfunction [<a href="#rid1">1</a>]. Graft function will recover in most patients after a few weeks, and retransplantation is avoided due to the high associated mortality in this context [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/1492.html" rel="external">"Short-term mechanical circulatory assist devices"</a> and  <a class="medical medical_review" href="/d/html/3459.html" rel="external">"Treatment of advanced heart failure with a durable mechanical circulatory support device"</a> and  <a class="medical medical_review" href="/d/html/87834.html" rel="external">"Management of long-term mechanical circulatory support devices"</a>.)</p><p class="headingAnchor" id="H20689341"><span class="h2">Secondary graft dysfunction</span><span class="headingEndMark"> — </span>Allograft dysfunction can also occur as a result of recipient and procedural factors. Causes include hyperacute rejection and excessive volume or pressure load on the right ventricle. Unrecognized pulmonary hypertension in the recipient can result in RV failure immediately after allograft implantation. Extensive intraoperative bleeding can result in massive blood product transfusion requirements and can subject the vulnerable right ventricle to volume overload and RV dysfunction.</p><p class="headingAnchor" id="H20689183"><span class="h3">Hyperacute rejection</span><span class="headingEndMark"> — </span>Hyperacute rejection, the most ominous cause of perioperative LV dysfunction, is extremely rare and is caused by the presence of pre-formed recipient antibodies that cross-react with endothelial epitopes on the allograft [<a href="#rid15">15</a>]. It is most often due to inadvertent implantation of an ABO-mismatched allograft. It may also be seen in highly sensitized patients, such as multiparous women or those with multiple prior transfusions, who have developed pre-formed cytotoxic antibodies that are directed against major histocompatibility (MHC) antigens on the donor heart. This form of rejection occurs within the first 24 hours after transplant and may be evident after reperfusion of the allograft in the operating room. Widespread endothelial damage leads to global ischemia and catastrophic allograft failure.</p><p class="headingAnchor" id="H100130302"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Strategies to avoid secondary graft dysfunction include double-checking ABO blood type matching of donor and recipients, preoperative screening of transplant candidates for the presence of circulating pre-formed antibodies to MHC antigens, the use of virtual or prospective crossmatching of sensitized transplant candidates with potential donors [<a href="#rid16">16</a>], evaluation of recipients for pulmonary hypertension, and careful post-transplant hemodynamic and volume management. Patients with hyperacute rejection are treated with plasmapheresis in combination with corticosteroids, antilymphocyte antibodies, and intravenous immunoglobulin (see  <a class="medical medical_review" href="/d/html/3520.html" rel="external">"Heart transplantation in adults: Treatment of rejection"</a>). <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a>, a monoclonal antibody that binds to the compliment protein C5 and inhibits assembly of the membrane attack complex, can be used as salvage treatment in combination with the above therapies, but experience with this drug in heart transplantation is limited [<a href="#rid17">17,18</a>]. Management of secondary graft dysfunction is otherwise similar to that for PGD.</p><p class="headingAnchor" id="H6"><span class="h1">LATE GRAFT DYSFUNCTION</span><span class="headingEndMark"> — </span>Ventricular dysfunction that develops weeks to years after transplantation is most often due to allograft rejection or to ischemia caused by allograft coronary artery disease, but may also be due to infectious myocarditis or occasionally may occur without any documentable cause.</p><p class="headingAnchor" id="H7"><span class="h2">Rejection</span><span class="headingEndMark"> — </span>The development of left, right, or biventricular dysfunction in the weeks to months following cardiac transplantation is most often due to acute allograft rejection [<a href="#rid19">19</a>]. Most cases of acute rejection are diagnosed by routine surveillance endomyocardial biopsy at a time when the patient is asymptomatic and ventricular function is normal [<a href="#rid7">7</a>]. The symptoms that occur typically represent signs of volume overload or low cardiac output. These include dyspnea on exertion or at rest, paroxysmal nocturnal dyspnea, orthopnea, abdominal bloating, fatigue, and syncope or near-syncope. Other clinical findings that suggest the presence of rejection include new right- or left-sided ventricular gallop sounds on auscultation, elevated jugular venous pressure, or new atrial or ventricular arrhythmias. (See  <a class="medical medical_review" href="/d/html/3519.html" rel="external">"Heart transplantation in adults: Diagnosis of allograft rejection", section on 'Clinical manifestations'</a>.)</p><p>Acute cellular rejection occurs with decreasing frequency and severity over time. Episodes may be associated with recent changes in immunosuppression, medication noncompliance, or unrecognized drug interactions that lead to decreased serum concentrations of immunosuppressive drugs. Antibody-mediated rejection is increasingly recognized as a cause of late graft dysfunction and may occur years after transplantation. Risk factors for antibody-mediated rejection include a history of pre-formed antibodies to human leukocyte antigens (HLA) prior to transplant, a positive pretransplant crossmatch, female sex, multiparity, and a history of prior transplant [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of rejection is typically made by endomyocardial biopsy. Asymptomatic rejection is usually detected by routine "protocol" endomyocardial biopsy. The biopsy can also confirm the presence of rejection and identify the type and severity of rejection in patients who develop signs or symptoms of ventricular dysfunction. Noninvasive imaging techniques (eg, echocardiography) may also reveal ventricular dysfunction or evidence of severe diastolic dysfunction but cannot discriminate between graft dysfunction caused by rejection versus other causes. (See  <a class="medical medical_review" href="/d/html/3519.html" rel="external">"Heart transplantation in adults: Diagnosis of allograft rejection", section on 'Acute cellular rejection'</a> and  <a class="medical medical_review" href="/d/html/3519.html" rel="external">"Heart transplantation in adults: Diagnosis of allograft rejection", section on 'Acute antibody-mediated (humoral) rejection'</a>.)</p><p>Sampling error associated with endomyocardial biopsy may result in underestimation of the severity of rejection. As a result, the absence of pathologic evidence for severe rejection in the presence of unexplained ventricular dysfunction, heart failure, or shock should not deter treatment for rejection.</p><p>The treatment of acute allograft rejection is discussed separately. In severe cases, inotropic agents and temporary mechanical circulatory support may be needed to support the patient while antirejection and heart failure therapies are initiated. (See  <a class="medical medical_review" href="/d/html/3520.html" rel="external">"Heart transplantation in adults: Treatment of rejection"</a> and  <a class="medical medical_review" href="/d/html/1492.html" rel="external">"Short-term mechanical circulatory assist devices"</a>.)</p><p>Graft ventricular function often returns to normal with successful treatment of rejection, even if severe. The long-term prognosis can be favorable; however, repeated episodes of severe acute cellular rejection are associated with a greater likelihood of persistent graft dysfunction due to myocardial fibrosis and/or the development of cardiac allograft vasculopathy [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/3523.html" rel="external">"Heart transplantation in adults: Prognosis"</a>.)</p><p class="headingAnchor" id="H19973953"><span class="h2">Cardiac allograft vasculopathy</span><span class="headingEndMark"> — </span>Cardiac allograft vasculopathy or transplant coronary artery disease refers to the development of a diffuse vasculopathy that is limited to the allograft, is related to both immunologic and nonimmunologic factors, and can lead to graft dysfunction months to years after transplantation. Allograft vasculopathy should always be considered as a possible cause for graft dysfunction occurring after the first year post-transplantation. (See  <a class="medical medical_review" href="/d/html/3517.html" rel="external">"Heart transplantation in adults: Cardiac allograft vasculopathy pathogenesis and risk factors"</a> and  <a class="medical medical_review" href="/d/html/3522.html" rel="external">"Heart transplantation: Clinical manifestations, diagnosis, and prognosis of cardiac allograft vasculopathy"</a>.)</p><p>Based upon International Society of Heart and Lung Transplantation registry data, the prevalence of allograft vasculopathy is approximately 8 percent within the first year posttransplantation, 20 percent within five years, and 47 percent within 10 years [<a href="#rid22">22</a>]. The diagnosis is usually made by coronary angiography, but it is generally acknowledged that angiography underestimates this diffuse, concentric process. As a result, many patients who develop clinical events that are presumably due to transplant vasculopathy may not have angiographically significant disease.</p><p>Because of these limitations, adjuncts to angiography have been sought that might improve the detection of early arterial wall remodeling seen in transplant vasculopathy. Intravascular ultrasound provides a quantitative assessment of intimal wall hyperplasia and vascular lumen area, but it is still mainly used as a research tool. Optical coherence tomography, analogous to ultrasound imaging except that it uses light instead of sound, has also been used to detect vascular wall changes associated with allograft vasculopathy in both adult and pediatric heart transplant recipients [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/d/html/3522.html" rel="external">"Heart transplantation: Clinical manifestations, diagnosis, and prognosis of cardiac allograft vasculopathy", section on 'Diagnosis and evaluation'</a>.)</p><p>The clinical features and outcomes of allograft vasculopathy are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3522.html" rel="external">"Heart transplantation: Clinical manifestations, diagnosis, and prognosis of cardiac allograft vasculopathy"</a> and  <a class="medical medical_review" href="/d/html/3518.html" rel="external">"Heart transplantation in adults: Arrhythmias"</a> and  <a class="medical medical_review" href="/d/html/3524.html" rel="external">"Heart Transplantation: Prevention and treatment of cardiac allograft vasculopathy"</a>.)</p><p>Summarized briefly:</p><p class="bulletIndent1"><span class="glyph">●</span>Silent myocardial infarction, sudden death, and progressive heart failure are common presentations of transplant vasculopathy. Classic anginal chest pain is infrequent due to the presence of both afferent and efferent allograft denervation [<a href="#rid25">25</a>]. Affected patients progress at a variable rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapy of established vasculopathy is limited [<a href="#rid7">7,26</a>]. Palliative percutaneous coronary interventions are often performed in patients with discrete lesions amenable to these approaches. Percutaneous coronary intervention is associated with an excellent procedural success rate, but a high incidence of restenosis or new lesion progression is observed [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allograft vasculopathy remains the most common barrier to long-term survival [<a href="#rid7">7,27</a>]. In one report of 54 patients with at least 40 percent stenosis in one or more coronary arteries, overall survival was 67, 44, and 17 percent at one, two, and five years [<a href="#rid27">27</a>]. Survival varied with disease severity, being worst in patients with three-vessel disease (13 percent at two years).</p><p></p><p>Retransplantation is reserved for patients with diffuse, multi-vessel coronary artery disease who develop severe graft dysfunction and/or marked symptoms of heart failure or ischemia and who have no contraindications to retransplantation. (See  <a class="medical medical_review" href="/d/html/3523.html" rel="external">"Heart transplantation in adults: Prognosis", section on 'Repeat cardiac transplantation'</a>.) </p><p class="headingAnchor" id="H9"><span class="h2">Infectious myocarditis</span><span class="headingEndMark"> — </span>Toxoplasma gondii and cytomegalovirus are two opportunistic infections that can produce acute myocarditis in immunosuppressed transplant recipients. The diagnosis is established by identifying the infectious organisms or multinucleated giant cells in endomyocardial biopsy samples. Standard treatment for these infections is employed, often while attempting to attenuate the degree of chronic immunosuppression. (See  <a class="medical medical_review" href="/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Recurrent myocardial disease</span><span class="headingEndMark"> — </span>In rare patients, recurrence of the initial myocardial disease that resulted in failure of the native heart can lead to failure of the cardiac allograft. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Amyloidosis, a disorder in which transplantation is not often performed because of frequently severe extracardiac amyloid deposition. (See  <a class="medical medical_review" href="/d/html/122846.html" rel="external">"Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Giant cell myocarditis and sarcoidosis, which are rare diseases treated with transplantation. (See  <a class="medical medical_review" href="/d/html/3516.html" rel="external">"Causes of dilated cardiomyopathy"</a> and  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary hemochromatosis, in which recurrent disease is avoidable by ongoing therapy to prevent iron overload. (See  <a class="medical medical_review" href="/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis"</a> and  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p></p><p class="headingAnchor" id="H1797714727"><span class="h2">Nonspecific allograft dysfunction</span><span class="headingEndMark"> — </span>Nonspecific allograft dysfunction is generally defined as graft dysfunction in the absence of histologic evidence of rejection on endomyocardial biopsy (ie, lack of either cellular inflammatory infiltrate or positive staining for antibody or complement deposition), significant allograft vasculopathy, or recurrent myocardial disease. A sizable number of patients with nonspecific allograft dysfunction without evidence of occlusive allograft vasculopathy on coronary angiography have evidence of significant obliterative vasculopathy affecting the arterioles and/or intra-myocardial vessels and in some cases sparing the major epicardial vessels on examination of the explanted heart at the time of death or re-transplantation [<a href="#rid15">15</a>]. Additionally, a small number of patients with acute cellular or antibody-mediated rejection will have unremarkable endomyocardial biopsy specimens due to sampling error [<a href="#rid28">28</a>]. In these patients, intensification of immunosuppression (eg, with high-dose corticosteroids, antithymocyte globulin) has been associated with clinical improvement [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/3439.html" rel="external">"Patient education: Heart transplantation (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY</span><span class="headingEndMark"> — </span>There is a short differential diagnosis for graft dysfunction after orthotopic cardiac transplantation that varies with time posttransplant at diagnosis. Heart failure with either reduced or preserved ejection fraction may be identified.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early graft dysfunction </strong>– Early allograft dysfunction occurring in the operative and immediate postoperative period is often due to ischemic and reperfusion injury during allograft procurement, transport, and reimplantation or the use of a suboptimal donor heart. Hyperacute rejection also can occur during this time period but is rare. Mild early allograft dysfunction is treated with inotropic agents, and we have a low threshold to initiate temporary mechanical circulatory support (such as the use of an intraaortic balloon pump, extracorporeal membrane oxygenator, or a percutaneous ventricular assist device) in cases of moderate or severe primary graft dysfunction. (See <a class="local">'Early graft dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late graft dysfunction</strong> –<strong> </strong>The most important causes of late graft dysfunction are allograft rejection and vasculopathy. Prompt treatment of allograft rejection can result in improvement in graft function even in patients with cardiogenic shock. Empiric therapy may be indicated if the clinical suspicion is high, even in the absence of biopsy-proven rejection. (See  <a class="medical medical_review" href="/d/html/3520.html" rel="external">"Heart transplantation in adults: Treatment of rejection"</a>.)</p><p></p><p class="headingAnchor" id="H554245"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Allen S Anderson, MD, FACC, FAHA, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kobashigawa J, Zuckermann A, Macdonald P, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant 2014; 33:327.</a></li><li><a class="nounderline abstract_t">Buchan TA, Moayedi Y, Truby LK, et al. Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis. J Heart Lung Transplant 2021; 40:642.</a></li><li><a class="nounderline abstract_t">Russo MJ, Iribarne A, Hong KN, et al. Factors associated with primary graft failure after heart transplantation. Transplantation 2010; 90:444.</a></li><li><a class="nounderline abstract_t">Russo MJ, Chen JM, Sorabella RA, et al. The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 2007; 133:554.</a></li><li><a class="nounderline abstract_t">Appleyard RF, Cohn LH. Myocardial stunning and reperfusion injury in cardiac surgery. J Card Surg 1993; 8:316.</a></li><li><a class="nounderline abstract_t">García-Poblete E, Fernández H, Alvarez L, et al. Structural and ultrastructural study of the myocardium after 24-hour preservation in University of Wisconsin solution. Histol Histopathol 1997; 12:375.</a></li><li><a class="nounderline abstract_t">Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant 2000; 19:909.</a></li><li><a class="nounderline abstract_t">Potapov EV, Loebe M, Hübler M, et al. Medium-term results of heart transplantation using donors over 63 years of age. Transplantation 1999; 68:1834.</a></li><li><a class="nounderline abstract_t">Marelli D, Laks H, Fazio D, et al. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant 2000; 19:496.</a></li><li><a class="nounderline abstract_t">Jeevanandam V, Furukawa S, Prendergast TW, et al. Standard criteria for an acceptable donor heart are restricting heart transplantation. Ann Thorac Surg 1996; 62:1268.</a></li><li><a class="nounderline abstract_t">Bitargil M, Haddad O, Pham SM, et al. Controlled temperatures in cold preservation provides safe heart transplantation results. J Card Surg 2022; 37:732.</a></li><li><a class="nounderline abstract_t">Pahuja M, Case BC, Molina EJ, Waksman R. Overview of the FDA's Circulatory System Devices Panel virtual meeting on the TransMedics Organ Care System (OCS) Heart - portable extracorporeal heart perfusion and monitoring system. Am Heart J 2022; 247:90.</a></li><li><a class="nounderline abstract_t">Ardehali A, Esmailian F, Deng M, et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet 2015; 385:2577.</a></li><li><a class="nounderline abstract_t">Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33:996.</a></li><li><a class="nounderline abstract_t">McNamara D, Di Salvo T, Mathier M, et al. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression. J Heart Lung Transplant 1996; 15:506.</a></li><li class="breakAll">Emery RW, Miller LW. Handbook of Cardiac Transplantation, Lippincott Williams &amp; Wilkins, Philadelphia 1996. p.129.</li><li><a class="nounderline abstract_t">Law YM, Nandi D, Molina K, et al. Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients. Cardiol Young 2020; 30:107.</a></li><li><a class="nounderline abstract_t">Kittleson MM, Patel N, Chang DH, et al. Eculizumab for antibody-mediated rejection in heart transplantation: A case-control study. Clin Transplant 2021; 35:e14454.</a></li><li><a class="nounderline abstract_t">Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011. J Heart Lung Transplant 2011; 30:1078.</a></li><li><a class="nounderline abstract_t">Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22:58.</a></li><li><a class="nounderline abstract_t">Skowronski EW, Epstein M, Ota D, et al. Right and left ventricular function after cardiac transplantation. Changes during and after rejection. Circulation 1991; 84:2409.</a></li><li><a class="nounderline abstract_t">Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38:1056.</a></li><li><a class="nounderline abstract_t">McGovern E, Hosking MCK, Balbacid E, et al. Optical Coherence Tomography for the Early Detection of Coronary Vascular Changes in Children and Adolescents After Cardiac Transplantation: Findings From the International Pediatric OCT Registry. JACC Cardiovasc Imaging 2019; 12:2492.</a></li><li><a class="nounderline abstract_t">Clemmensen TS, Holm NR, Eiskjær H, et al. Detection of early changes in the coronary artery microstructure after heart transplantation: A prospective optical coherence tomography study. J Heart Lung Transplant 2018; 37:486.</a></li><li><a class="nounderline abstract_t">Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. N Engl J Med 1991; 324:1791.</a></li><li><a class="nounderline abstract_t">Halle AA 3rd, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995; 26:120.</a></li><li><a class="nounderline abstract_t">Keogh AM, Valantine HA, Hunt SA, et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant 1992; 11:892.</a></li><li><a class="nounderline abstract_t">Bhalodolia R, Cortese C, Graham M, Hauptman PJ. Fulminant acute cellular rejection with negative findings on endomyocardial biopsy. J Heart Lung Transplant 2006; 25:989.</a></li><li><a class="nounderline abstract_t">Costanzo-Nordin MR, Heroux AL, Radvany R, et al. Role of humoral immunity in acute cardiac allograft dysfunction. J Heart Lung Transplant 1993; 12:S143.</a></li></ol></div><div id="topicVersionRevision">Topic 3526 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24661451" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Report from a consensus conference on primary graft dysfunction after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33947602" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence and impact of primary graft dysfunction in adult heart transplant recipients: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20622755" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Factors associated with primary graft failure after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17258599" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8461524" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Myocardial stunning and reperfusion injury in cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9151126" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Structural and ultrastructural study of the myocardium after 24-hour preservation in University of Wisconsin solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044685" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10628759" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Medium-term results of heart transplantation using donors over 63 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10808159" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The use of donor hearts with left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8893556" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Standard criteria for an acceptable donor heart are restricting heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35060167" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Controlled temperatures in cold preservation provides safe heart transplantation results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35150637" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Overview of the FDA's Circulatory System Devices Panel virtual meeting on the TransMedics Organ Care System (OCS) Heart - portable extracorporeal heart perfusion and monitoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25888086" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25242124" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8771506" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8771506" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31875805" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34402096" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Eculizumab for antibody-mediated rejection in heart transplantation: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21962016" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12531414" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1959196" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Right and left ventricular function after cardiac transplantation. Changes during and after rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31548031" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30031706" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Optical Coherence Tomography for the Early Detection of Coronary Vascular Changes in Children and Adolescents After Cardiac Transplantation: Findings From the International Pediatric OCT Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29128426" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Detection of early changes in the coronary artery microstructure after heart transplantation: A prospective optical coherence tomography study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2038368" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797740" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1420237" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16890123" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fulminant acute cellular rejection with negative findings on endomyocardial biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8476884" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of humoral immunity in acute cardiac allograft dysfunction.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
